- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05800704
Support of Colonization Resistance of the Gut Microbiota With the Synbiotic Food Supplement Nagasin®
Randomized, Controlled, Double-blind, Parallel, Multicentric Study to Investigate Support of the Colonization Resistance of the Gut Microbiota With the Synbiotic Food Supplement Nagasin® After Disturbance by Antimicrobial Treatment
The aim of this randomized, controlled, double-blind, parallel, multicentric trial is to investigate wether the synbiotic food supplement Nagasin® can support the colonization resistance of the gut microbiota after disturbance by antimicrobial treatment.
The main question is whether Nagasin® can prevent any increase in abundance of C.difficile within the first four weeks after antimicrobial treatment for a C. difficile infection.
Participants will receive Nagasin® or the comparator as a food supplement during the first four weeks after antimicrobial treatment for a C. difficile episode.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Isabelle M Frey-Wagner, PhD
- Phone Number: +41 76 426 33 10
- Email: isabelle.frey@imm.uzh.ch
Study Locations
-
-
-
Bern, Switzerland, 3010
- Recruiting
- Inselspital Bern
-
Contact:
- Benjamin Misselwitz
- Phone Number: +41 31 664 04 30
- Email: benjamin.misselwitz@insel.ch
-
-
BL
-
Liestal, BL, Switzerland, 4410
- Not yet recruiting
- Kantonsspital Baselland
-
Contact:
- Emanuel Burri, MD
-
-
LU
-
Luzern, LU, Switzerland, 6000
- Not yet recruiting
- Luzerner Kantonsspital
-
Contact:
- Simon Bütikofer, MD
-
-
ZH
-
Zurich, ZH, Switzerland, 8091
- Recruiting
- University Hospital Zurich
-
Contact:
- Luc Biedermann, MD
- Phone Number: + 41 44 255 11 11
- Email: luc.biedermann@usz.ch
-
Zürich, ZH, Switzerland, 8063
- Not yet recruiting
- Stadtspital Zürich
-
Contact:
- Bernhard Morell, MD
-
-
Zurich
-
Winterthur, Zurich, Switzerland, 8400
- Recruiting
- Kantonsspital Winterthur
-
Contact:
- Michael Osthoff, MD
- Phone Number: +41 52 266 2757
- Email: michael.osthoff@ksw.ch
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- C. difficile infection diagnosis
- antimicrobial treatment (e.g. metronidazole, vancomycin or fidaxomicin) for C. difficile infection at ICF
- Written informed consent by the participant after information about the research project
Exclusion Criteria:
- total parenteral nutrition
- insulin-dependent (type 1) diabetes
severe disease defined as any of the following:
- WBC > 30,000 or < 1000 cells/mm3
- Neutropenia < 500 x 10^9 per liter
- ICU patient at time C. difficile infection diagnosed
- In case no hematology values are available, presence of severe can be evaluated by the local principal investigator or his designee
is severely immunocompromised as defined by any of the following:
- active malignancy receiving severe immunosuppressive chemotherapy with subsequent leukopenia (as defined above)
- long-term systemic steroid therapy ≥ 30 mg / d
- recipients of stem cell transfer (≤ 12 months)
- severe inborne immune deficiency or severe immunosuppressive therapy as evaluated by the investigator
- HIV patients with low CD4+ cell count (< 200 x 10^9 per liter)
- Inflammatory bowel disease patients if:
- severe ulcerative colitis (classified as endoscopic Mayo = 3 (max. 30 days old) or as evaluated by investigator)
- Severe Crohn's disease with acute penetrating complication (abscess and/or actively draining fistulae) or as evaluated by investigator
- Liver cirrhosis (classified as Child C) with clinically significant portal hypertension and/or low thrombocyte count (20 × 10^9 per liter)
- Acute pancreatitis
- prosthetic heart valves or endocarditis
- consumption of other high-dose (>10^10 cfu/dose) probiotic products during the study period.
- Inability to understand and follow study procedures
- prosthetic heart valves or endocarditis
- consumption of other high-dose (>10^10 cfu/dose) probiotic products during the study period.
- Inability to understand and follow study procedures
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Nagasin®
consumption of Nagasin® (synbiotic food supplement) once per day for four weeks
|
Lactobacillus, Lactococcus and Bifidobacteria strains with antimicrobial effect against C. difficile
|
Placebo Comparator: Comparator
consumption of the comparator (maltodextrin) once per day for four weeks
|
maltodextrin (placebo comparator)
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
C. difficile relative abundance
Time Frame: at 1, 2 and 4 weeks after completion of antimicrobial treatment for CDI
|
any change of C. difficile relative abundance during the first four weeks after antimicrobial treatment for CDI.
|
at 1, 2 and 4 weeks after completion of antimicrobial treatment for CDI
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Gut microbiota
Time Frame: at 1, 2, 4 and 8 weeks after completion of antimicrobial treatment for CDI
|
Gut microbiota diversity and taxonomic composition
|
at 1, 2, 4 and 8 weeks after completion of antimicrobial treatment for CDI
|
Abundance of antibiotic diarrhea associated pathogens
Time Frame: at 1, 2, 4 and 8 weeks after completion of antimicrobial treatment for CDI
|
Abundance of other pathogens that are involved in antibiotic associated diarrhea e.g. S. aureus and K. oxytoca
|
at 1, 2, 4 and 8 weeks after completion of antimicrobial treatment for CDI
|
C. difficile toxins
Time Frame: at 1, 2, 4 and 8 weeks after completion of antimicrobial treatment for CDI
|
Presence and amount of C. difficile toxins
|
at 1, 2, 4 and 8 weeks after completion of antimicrobial treatment for CDI
|
Toxin forming C. difficile strains
Time Frame: at 1, 2, 4 and 8 weeks after completion of antimicrobial treatment for CDI
|
Presence of toxin forming C. difficile strains
|
at 1, 2, 4 and 8 weeks after completion of antimicrobial treatment for CDI
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Study Chair: Isabelle M Frey-Wagner, PhD, University or Zurich, Institute of Medical Microbiology
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- BASEC 2022-01318
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on C. Difficile Enteritis
-
Brigham and Women's HospitalCenters for Disease Control and Prevention; Harvard Pilgrim Health Care Institute and other collaboratorsRecruitingC. DifficileUnited States
-
DaniscoUniversity of TurkuCompleted
-
DeinoveRecruitingClostridium Difficile (C. Difficile)United States, Canada
-
Providence Holy Cross Medical CenterUnknown
-
State University of New York at BuffaloWithdrawnC. Difficile InfectionUnited States
-
Finch Research and Development LLC.Medpace, Inc.CompletedClostridium Difficile Infection | Recurrent Clostridium Difficile Infection | C. Diff | CDI | Recurrent C. Diff | rCDI | C. Difficile | Recurrent CDI | FMT | Fecal Microbiota | Fecal TransplantUnited States, Canada
-
University of Wisconsin, MadisonAgency for Healthcare Research and Quality (AHRQ)Enrolling by invitationClostridium Difficile Infection | Clostridium Difficile | C Difficile ColitisUnited States
-
The University of Texas Health Science Center,...Kelsey Research Foundation; Roderick MacDonald Research Fund at Baylor St.... and other collaboratorsCompleted
-
Vedanta Biosciences, Inc.Not yet recruitingClostridium Difficile Infection Recurrence | Recurrent Clostridium Difficile Infection | Clostridium Difficile | Diarrhea Infectious | CDI | Clostridium Difficile Infections | Clostridioides Difficile Infection | C.Difficile Diarrhea | Clostridioides Difficile Infection Recurrence | C. Diff Infection
-
Memorial Sloan Kettering Cancer CenterCompletedCancer | C. Difficile InfectionUnited States